Multinational Law Firm Advises Bioventus on Initial IPO

An initial IPO is a public offering in which shares of a company are sold to institutional investors and usually also to retail investors. An IPO is typically underwritten by one or more investment banks, who also arrange for the shares to be listed on one or more stock exchanges.

Bioventus Inc. has announced the pricing of its initial public offering of 8 million shares of Class A common stock at a public offering price of US$13 per share.

The Company’s Class A common stock began trading on the Nasdaq Global Select Market under the symbol “BVS.”

Latham & Watkins LLP represents Bioventus, Inc. in the offering with a corporate team led by Boston/New York partner Wesley Holmes and Orange County / New York partner Charles Ruck, with associates Katie Lovejoy, Jessica Lim, Jonathan Hernandez, and Hera Liao.

Bioventus is a global leader of innovations for active healing and surgical orthobiologics with a comprehensive portfolio of clinically efficacious and cost-effective solutions for patients, physicians and payers.

Latham is an American multinational law firm. Founded in 1934 in Los Angeles, California, Latham is the second-largest law firm in the world by revenue. As of 2021, Latham is also one of the most profitable law firms in the world, with profits per partner exceeding US$4.5 million.

Advice was also provided on tax matters by Washington, D.C. partner Andrea Ramezan-Jackson, with associate Eli McCrain; on benefits and compensation matters by New York counsel Rifka Singer, with associate Daniel Gocek; on intellectual property matters by Bay Area partner Judith Hasko, with associate Seth Appiah-Opoku; on public company representation matters by New York partner Dennis Craythorn, with associate Kate Pritchard; on FDA regulatory matters by Washington, D.C. partner Elizabeth Richards, with associate Barrett Tenbarge; and on healthcare regulatory matters by Washington, D.C. partners Stuart Kurlander and Eric Greig.